Diabetes meds reassurance

Following post-marketing reports of pancreatitis and pancreatic cancer in patients using incretin-based drugs, such as sitagliptin, liraglutide and saxagliptin, the FDA and EMA launched a comprehensive safety analysis.

With the year-long investigation now complete, agency officials are not recommending any changes to the product information but acknowledged a number of confounding factors that make it too early to definitely rule out a causal link.